Abstract 2473: A novel anti-PD-1 and proIL-2 bifunctional fusion protein delivers potent anti-tumor activity via PD-1 checkpoint inhibition and tumor selective IL-2R agonism preferentially on antigen specific T cells
Preclinical study demonstrates tumor inhibition by a PD-1-proIL-2v fusion protein in resistant tumor models, highlighting selective immune activation.
Key Points
Bifunctional PD-1-proIL-2v delivers potent antitumor activity by combining immune checkpoint blockade with tumor-selective interleukin-2 receptor agonism.
In mouse models resistant to PD-1 checkpoint inhibition, the protein induced tumor regression at 0.1 mg/kg and expanded tumor-infiltrating CD8+ T cells.
A four-week repeat-dose safety evaluation in nonhuman primates demonstrated no overt toxicity; mouse and primate models, clinical validation pending.